Annette Hudler, DO
Internal Medicine · Purcellville, VANPI 1487699161
Payments from drug & device makers
Across 428 payments — averaging $17.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- AstraZeneca$1K
- AbbVie$958
- Pfizer$517
- Lilly USA, LLC$434
- GSK$296
- plus $2K from 31 others
What the payments were for
- Food & beverage$7,23498%
- Education$1612%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 93 | $1,447 |
| AstraZeneca | 71 | $1,406 |
| AbbVie(2 entities) | 61 | $958 |
| Pfizer | 29 | $517 |
| Lilly USA, LLC | 23 | $434 |
| GSK | 17 | $296 |
| Sanofi-aventis U.S. LLC | 15 | $252 |
| Takeda Pharmaceuticals U.S.A., Inc. | 20 | $214 |
| Astellas Pharma US Inc | 6 | $208 |
| Merck | 12 | $189 |
| Bayer | 9 | $154 |
| Currax Pharmaceuticals LLC | 11 | $148 |
| Boehringer Ingelheim | 7 | $147 |
| Johnson & Johnson | 6 | $134 |
| Biohaven Pharmaceutical Holding Company Ltd. | 10 | $131 |
| Eisai Inc. | 5 | $106 |
| Exact Sciences | 3 | $82 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $74 |
| Amgen | 2 | $57 |
| Amneal Pharmaceuticals LLC | 2 | $55 |
| Idorsia Pharmaceuticals US Inc | 3 | $46 |
| Novartis | 2 | $36 |
| Abbott | 2 | $33 |
| Amarin Pharma, Inc. | 2 | $32 |
| Vanda Pharmaceuticals Inc. | 1 | $30 |
| Mylan Specialty L.p. | 1 | $22 |
| Shire North American Group Inc | 1 | $22 |
| IBSA Pharma Inc. | 1 | $21 |
| PBG Puerto Rico LLC | 1 | $21 |
| Arbor Pharmaceuticals, Inc. | 1 | $17 |
| Sanofi Pasteur Inc. | 1 | $17 |
| Biohaven Pharmaceuticals, Inc. | 1 | $17 |
| Teva Pharmaceuticals USA, Inc. | 1 | $17 |
| Upsher-smith Laboratories LLC | 1 | $16 |
| Avion Pharmaceuticals | 1 | $15 |
| Esperion Therapeutics, Inc. | 1 | $14 |
| Nalpropion Pharmaceuticals LLC | 1 | $13 |
How this compares
$7,395 in reported general payments places this provider in the 90th percentile of 2,724 internal medicine providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 58 | $92,475 |
| EliquisApixaban | 86 | $85,043 |
| FarxigaDapagliflozin Propanediol | 53 | $63,307 |
| JardianceEmpagliflozin | 35 | $41,420 |
| MounjaroTirzepatide | 30 | $38,285 |
| TrulicityDulaglutide | 19 | $26,219 |
| RybelsusSemaglutide | 13 | $22,522 |
| Tresiba Flextouch U-100Insulin Degludec | 26 | $22,170 |
| JanuviaSitagliptin Phosphate | 14 | $19,932 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 14 | $18,576 |
| MyrbetriqMirabegron | 19 | $17,243 |
| Tresiba Flextouch U-200Insulin Degludec | 14 | $15,495 |
| Xigduo XrDapaglifloz Propaned/Metformin | 13 | $12,698 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 14 | $9,981 |
| Breo ElliptaFluticasone/Vilanterol | 18 | $7,996 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $1,447 | $114,99771 claims |
| PfizerEliquis | $517 | $85,04386 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $1,406 | $73,28867 claims |
| Lilly USA, LLCMounjaro, Trulicity | $434 | $64,50449 claims |
| Boehringer IngelheimJardiance | $147 | $41,42035 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $296 | $26,57232 claims |
| MerckJanuvia | $189 | $19,93214 claims |
| Astellas Pharma US IncMyrbetriq | $208 | $17,24319 claims |
| AbbVieSynthroid | $958 | $7,404106 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $55 | $3,653344 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,724 internal medicine providers in Virginia.
Other internal medicine in Purcellville
- Leroy VaughanRichmond$20.8M
- James ClarkCharlottesville$16.2M
- Nabil AndrawisBurke$8.5M
- Mary BlumbergNorfolk$6.5M
- David RamstadSuffolk$5.8M
- Andrew PoklepovicRichmond$4.6M
- Nashwa GabraBurke$4.3M
- Michael DevittCharlottesville$3.5M
- Richard JacksonRichmond$2.5M
- Sue BrownCharlottesville$2.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.